GLP-1 Drug Pricing Guides
Current prices, self-pay discounts, insurance copays, TrumpRx deals, and Medicare coverage for every major GLP-1 weight loss and diabetes drug.
FeaturedGLP-1 Drug Pricing Trends: 2023–2026
Charts tracking how Ozempic, Wegovy, Mounjaro, and Zepbound prices changed across list price, self-pay, and insurance channels over 3 years.
View charts →Retatrutide Predicted Pricing: What Eli Lilly's Triple Agonist Will Cost
Retatrutide is projected to launch at $1,000-$1,500/mo WAC in late 2027. We break down the pricing signals, market forces, and what patients can expect to pay.
View prices →GLP-1 Drug Pricing Guide: Best Prices as of April 2026
Complete guide to GLP-1 drug prices in April 2026 covering Ozempic, Wegovy, Mounjaro, Zepbound, Foundayo, compounded options, India generics, and government programs.
View prices → (Updated )Foundayo Pricing: April 2026
Foundayo (orforglipron) launched April 9, 2026 at $649/mo list price. LillyDirect self-pay from $149/mo. The only GLP-1 pill with no food restrictions.
View prices → (Updated )Mounjaro Pricing: April 2026
Mounjaro WAC at ~$1,080/mo. LillyDirect vials from $299/mo. TrumpRx live at ~$350/mo. Medicare copay $50/mo.
View prices → (Updated )Ozempic Pricing: April 2026
Ozempic WAC at ~$1,027/mo but best self-pay price is $199/mo for new patients via NovoCare. 2027 WAC cut to $675 announced.
View prices → (Updated )Wegovy Pricing: April 2026
Wegovy best price drops to $249/mo via new subscription program. TrumpRx portal live. Oral Wegovy pill also available.
View prices → (Updated )Zepbound Pricing: April 2026
Zepbound WAC at $1,086/mo but LillyDirect vials from $299/mo after December 2025 price cut. New KwikPen launched.
View prices →